News
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Laboratories Announces Third-Quarter 2022 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2022. For the quarter, revenue was $989.2 million, an increase of 10.4% from $895.9
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
LivaNova Reports Third-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2022.
Financial Summary and Highlights1
Premier, Inc. Reports Fiscal Year 2023 First Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 first quarter ended September 30, 2022.
"Our
Chemed Reports Third-Quarter 2022 Results - Increases 2022 Earnings Guidance
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Chemed Corporation to Present at the 2022 Credit Suisse Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 31st Annual Credit Suisse Healthcare Conference on Wednesday, November 9, 2022, at approximately 2:00 p.m
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Novocure Reports Third Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting from
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter of 2022.
Press release date / time: Monday, November 7, shortly after 22:05
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
Novocure (NASDAQ: NVCR) today announced a review article of anti-cancer mechanisms of action of Tumor Treating Fields (TTFields) has been published in the Journal of Molecular Cell Biology (JMCB).
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an